Radiofrequency (RF) Ablation Prospective Outcomes Study for Central Nervous System - RAPID for CNS

NCT06553625 · tracked via the Priya Life Science UK tracker

Sponsor

Boston Scientific Corporation

Phase

—

Started

2024-01-29

Last updated

2026-09-11

Condition(s) studied

Parkinson DiseaseDystoniaEssential TremorMovement Disorders

Investigational drug(s) / intervention(s)

Radiofrequency Ablation

Radiofrequency Ablation: Radiofrequency Ablation used in the central nervous system (CNS) in functional neurosurgery

Study summary

The objective of this study is to compile real-world outcomes of Boston Scientific commercially approved radiofrequency (RF) ablation systems used in the central nervous system (CNS) for use in functional neurosurgery.

Eligibility

Sex

ALL

Min age

—

Max age

—

Healthy volunteers

Inclusion Criteria: * Study candidate is scheduled to be treated with a commercially approved Boston Scientific RF system for pain or for CNS applications per local Directions for Use (DFU) * Signed a valid, IRB/EC/REB-approved informed consent form Exclusion Criteria: * Meets any contraindications per locally applicable Directions for Use (DFU) * Currently diagnosed with cognitive impairment, or exhibits any characteristic, that would limit study candidate's ability to assess pain relief or to complete study assessments

Primary outcome measure(s)

Change in patient's quality of life (QoL) during the study as compared with baseline — Up to 24-Months
Change in quality of life assessments during the study as compared with baseline

Trial sites (4)

Facility	City	Region	Status
Uniklinik Köln	Cologne	Germany	Recruiting
Universitaetsklinikum Dusseldorf	Düsseldorf	Germany	Recruiting
Universitaetsklinikum Wuerzburg	Würzburg	Germany	Recruiting
St. Georges Hospital	London	United Kingdom	Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06553625 on ClinicalTrials.gov ↗ ← All trials in the UK